CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Mutya Harsch

Profile

Mutya Harsch

Chief Financial Officer, Yarrow Bioscience, Inc.

Former. First published here October 28, 2026; built from records as of October 28, 2026.

Yarrow Bioscience, Inc. named Tyler Zeronda to succeed Mutya Harsch, effective July 27, 2026.1

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Yarrow Bioscience, Inc. (VYNE)
Pharmaceutical Preparations
Not statedFormer1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. July 27, 2026effective

    Yarrow Bioscience, Inc. named Tyler Zeronda to succeed Mutya Harsch, effective July 27, 2026. Profile of Tyler Zeronda.

    [1] Filing by Yarrow Bioscience, Inc., filed with the SEC on July 28, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Current report filed with the SEC, Yarrow Bioscience, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 28, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Mutya Harsch wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.